NASDAQ:KDNY Chinook Therapeutics (KDNY) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$40.29▼$40.5150-Day Range$38.66▼$40.3952-Week Range$18.34▼$40.51Volume4.92 million shsAverage Volume1.19 million shsMarket Capitalization$2.90 billionP/E RatioN/ADividend YieldN/APrice Target$38.14 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Chinook Therapeutics MarketRank™ ForecastAnalyst RatingHold2.23 Rating ScoreUpside/Downside5.6% Downside$38.14 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$45,587 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.30) to ($3.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.83 out of 5 starsMedical Sector954th out of 963 stocksBiotechnology Industry17th out of 19 stocks 1.1 Analyst's Opinion Consensus RatingChinook Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.23, and is based on 3 buy ratings, 10 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.14, Chinook Therapeutics has a forecasted downside of 5.6% from its current price of $40.39.Amount of Analyst CoverageChinook Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for KDNY. Previous Next 0.0 Dividend Strength Dividend YieldChinook Therapeutics does not currently pay a dividend.Dividend GrowthChinook Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KDNY. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 1 people have added Chinook Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chinook Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $45,587.00 in company stock.Percentage Held by Insiders16.79% of the stock of Chinook Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.15% of the stock of Chinook Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Chinook Therapeutics are expected to decrease in the coming year, from ($3.30) to ($3.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chinook Therapeutics is -11.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chinook Therapeutics is -11.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChinook Therapeutics has a P/B Ratio of 5.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Chinook Therapeutics (NASDAQ:KDNY) StockChinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.Read More KDNY Stock News HeadlinesAugust 8, 2023 | msn.comWedbush Downgrades Chinook Therapeutics (KDNY)August 2, 2023 | uk.finance.yahoo.comChinook Therapeutics, Inc. (KDNY)September 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 1, 2023 | markets.businessinsider.comExpert Ratings for Chinook TherapeuticsAugust 1, 2023 | msn.comWells Fargo Downgrades Chinook Therapeutics (KDNY)July 25, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KDNY, NETI, TALS, QUOTJuly 16, 2023 | fool.comChinook Therapeutics (NASDAQ: KDNY)June 21, 2023 | seekingalpha.comChinook: Surprising Acquisition By Novartis, Deal Should Go ThroughSeptember 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. June 17, 2023 | finance.yahoo.comChinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) CongressJune 16, 2023 | benzinga.comMoore Kuehn Encourages NETI, SURF, KDNY, and NEX Investors to Contact Law FirmJune 14, 2023 | businesswire.comCHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook ...June 13, 2023 | barrons.comKDNY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chinook Therapeutics, Inc. Is Fair to ShareholdersJune 13, 2023 | reuters.comNovartis buys Chinook for $3.5 bln in race to treat rare kidney diseaseJune 13, 2023 | markets.businessinsider.comWhy Are Chinook Therapeutics Shares Trading Higher TodayJune 12, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Chinook TherapeuticsJune 12, 2023 | finance.yahoo.comChinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) CongressJune 12, 2023 | seekingalpha.comNovartis Buys Chinook: M&A To Drive Future GrowthJune 12, 2023 | investorplace.comWhy Is Chinook Therapeutics (KDNY) Stock Up 58% Today?June 8, 2023 | markets.businessinsider.comChinook Shareholder Action ReminderMay 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), Chinook Therapeutics (KDNY) and Zoetis (ZTS)May 21, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNYMay 21, 2023 | benzinga.comChinook Shareholder NoticeMay 19, 2023 | seekingalpha.comChinook Therapeutics: Travere's Pain Is Chinook's GainMay 19, 2023 | benzinga.comChinook Investor AlertMay 18, 2023 | benzinga.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of InvestorsMay 17, 2023 | benzinga.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of InvestorsSee More Headlines Receive KDNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KDNY Company Calendar Last Earnings8/07/2023Today9/27/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KDNY CUSIPN/A CIK1435049 Webchinooktx.com Phone(206) 485-7241FaxN/AEmployees214Year FoundedN/APrice Target and Rating Average Stock Price Forecast$38.14 High Stock Price Forecast$43.00 Low Stock Price Forecast$32.00 Forecasted Upside/Downside-5.6%Consensus RatingHold Rating Score (0-4)2.23 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($3.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-187,870,000.00 Net Margins-4,199.93% Pretax Margin-4,115.56% Return on Equity-58.28% Return on Assets-44.72% Debt Debt-to-Equity RatioN/A Current Ratio5.82 Quick Ratio5.82 Sales & Book Value Annual Sales$6.13 million Price / Sales473.15 Cash FlowN/A Price / Cash FlowN/A Book Value$6.91 per share Price / Book5.85Miscellaneous Outstanding Shares71,810,000Free Float59,749,000Market Cap$2.90 billion OptionableOptionable Beta0.34 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Eric L. Dobmeier J.D. (Age 54)Pres, CEO & Director Comp: $972.19kMr. Tom Frohlich (Age 47)Chief Operating Officer Comp: $627.44kMr. Andrew James King D.V.M. (Age 43)Ph.D., Chief Scientific Officer Comp: $651.48kMr. Eric H. Bjerkholt M.B.A. (Age 63)Chief Financial Officer Ms. Sukhi ThethySr. VP of Fin. & AccountingMs. Noopur Batsha LiffickSr. VP of Investor Relations & Corp. CommunicationsMr. Kirk D. Schumacher J.D.Sr. VP & Gen. CounselMs. Jodi JamiesonSr. VP of HRDr. Alan Glicklich M.D. (Age 60)Exec. Officer Ms. Delphine Imbert Ph.D.Sr. VP of CMC & Technical OperationsMore ExecutivesKey CompetitorsZai LabNASDAQ:ZLABXenon PharmaceuticalsNASDAQ:XENEProtagonist TherapeuticsNASDAQ:PTGXREGENXBIONASDAQ:RGNXLife Time GroupNYSE:LTHView All CompetitorsInsiders & InstitutionsBarclays PLCBought 25,731 shares on 9/21/2023Ownership: 0.153%Alberta Investment Management CorpBought 30,000 shares on 8/24/2023Ownership: 0.042%Affinity Asset Advisors LLCSold 655,004 shares on 8/21/2023Ownership: 0.447%California State Teachers Retirement SystemBought 4,497 shares on 8/21/2023Ownership: 0.083%Osaic Holdings Inc.Sold 292 shares on 8/21/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions KDNY Stock - Frequently Asked Questions Should I buy or sell Chinook Therapeutics stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last twelve months. There are currently 10 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" KDNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KDNY, but not buy additional shares or sell existing shares. View KDNY analyst ratings or view top-rated stocks. What is Chinook Therapeutics' stock price forecast for 2023? 13 Wall Street research analysts have issued 12 month price objectives for Chinook Therapeutics' shares. Their KDNY share price forecasts range from $32.00 to $43.00. On average, they anticipate the company's share price to reach $38.14 in the next year. This suggests that the stock has a possible downside of 5.6%. View analysts price targets for KDNY or view top-rated stocks among Wall Street analysts. When is Chinook Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our KDNY earnings forecast. How were Chinook Therapeutics' earnings last quarter? Chinook Therapeutics, Inc. (NASDAQ:KDNY) posted its quarterly earnings data on Monday, August, 7th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.81) by $0.13. The business earned $1.01 million during the quarter, compared to analysts' expectations of $0.47 million. Chinook Therapeutics had a negative trailing twelve-month return on equity of 58.28% and a negative net margin of 4,199.93%. What ETFs hold Chinook Therapeutics' stock? ETFs with the largest weight of Chinook Therapeutics (NASDAQ:KDNY) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), AltShares Merger Arbitrage ETF (ARB), ProShares Merger ETF (MRGR), First Trust Merger Arbitrage ETF (MARB), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Simplify Propel Opportunities ETF (SURI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What other stocks do shareholders of Chinook Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR). What is Chinook Therapeutics' stock symbol? Chinook Therapeutics trades on the NASDAQ under the ticker symbol "KDNY." Who are Chinook Therapeutics' major shareholders? Chinook Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.94%), State Street Corp (4.05%), Alpine Associates Management Inc. (3.18%), Eventide Asset Management LLC (2.68%), Suvretta Capital Management LLC (2.43%) and Dimensional Fund Advisors LP (1.99%). Insiders that own company stock include Alan Glicklich, Andrew James King, Davis Jerel, Eric Bjerkholt, Eric Dobmeier, Mahesh Krishnan, Srinivas Akkaraju, Tom Frohlich, Versant Venture Capital Vii, L and William Mariner Greenman. View institutional ownership trends. What is Chinook Therapeutics' stock price today? One share of KDNY stock can currently be purchased for approximately $40.39. How much money does Chinook Therapeutics make? Chinook Therapeutics (NASDAQ:KDNY) has a market capitalization of $2.90 billion and generates $6.13 million in revenue each year. The company earns $-187,870,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis. How many employees does Chinook Therapeutics have? The company employs 214 workers across the globe. How can I contact Chinook Therapeutics? Chinook Therapeutics' mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The official website for the company is chinooktx.com. The company can be reached via phone at (206) 485-7241 or via email at investors@aduro.com. This page (NASDAQ:KDNY) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chinook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.